Tvardi Therapeutics TVRD

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet medical need. The company’s core activities involve advancing its pipeline of STAT3 inhibitors through preclinical and clinical development, leveraging its expertise in STAT3 biology to design therapies that selectively inhibit the transcription factor’s nuclear function without disrupting its essential role in mitochondrial cellular respiration. Tvardi Therapeutics, Inc. operates in the biopharmaceutical industry, specifically within the niche of targeted therapeutics for diseases driven by dysregulated STAT3 signaling, such as hepatocellular carcinoma and idiopathic pulmonary fibrosis.

The company generates revenue through the potential future commercialization of its product candidates, primarily TTI-101 and TTI-109, which are oral small molecule inhibitors of STAT3. Revenue is expected to arise from sales of these therapies upon regulatory approval, targeting patients with inflammatory and proliferative diseases such as cancer and fibrotic disorders. The company currently has no commercial products on the market and does not generate revenue from product sales, relying instead on funding from collaborations, licensing agreements, and capital markets to support its research and development activities.

The company operates through the following segments:

• Therapeutics Development: This segment encompasses the research, preclinical development, and clinical testing of Tvardi Therapeutics’ STAT3 inhibitors, including TTI-101 and TTI-109. The segment focuses on advancing these compounds through clinical trials for indications such as hepatocellular carcinoma and idiopathic pulmonary fibrosis, with the goal of demonstrating safety, efficacy, and pharmacokinetic profiles suitable for regulatory submission. TTI-101 is a first-generation direct STAT3 inhibitor currently in Phase 1b/2 development for hepatocellular carcinoma, while TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability, with a Phase 1 trial in healthy volunteers completed in 2026.

• Intellectual Property Management: This segment involves the acquisition, maintenance, and enforcement of patent rights and trade secrets related to Tvardi Therapeutics’ STAT3 inhibition platform. The company relies on in-licensed and owned patents covering compositions of matter, formulations, and methods of use for its product candidates across multiple jurisdictions, including the United States, Europe, and Asia. As of December 31, 2025, Tvardi Therapeutics held numerous issued and pending patent applications, including those related to self-emulsifying drug dispersion and spray-dried dispersion tablets of TTI-101, as well as the TTI-109 compound itself, to protect its innovations and support future commercialization.

Tvardi Therapeutics holds a distinctive position in the biopharmaceutical industry as one of the few companies pursuing direct inhibition of STAT3, a transcription factor historically considered undruggable, to treat inflammatory and proliferative diseases. The company differentiates itself through its proprietary understanding of STAT3’s dual role in nuclear transcription and mitochondrial function, enabling the design of inhibitors that avoid disrupting essential cellular respiration while targeting disease-driving pathways. Competitors in the STAT3-targeted space include Moleculin Biotech, Purple Biotech, and Scopus BioPharma, though Tvardi Therapeutics’ approach is distinguished by its oral small molecule format and mechanism of action focused on selective pY-STAT3 inhibition without inducing mitochondrial toxicity.

Tvardi Therapeutics serves patients suffering from inflammatory and proliferative diseases with significant unmet medical need, including those with hepatocellular carcinoma, idiopathic pulmonary fibrosis, and other fibrotic or proliferative conditions driven by dysregulated STAT3 signaling. The company’s clinical trials enroll individuals with advanced hepatocellular carcinoma who have progressed on prior systemic therapies, as well as patients with idiopathic pulmonary fibrosis, whether or not they are receiving concomitant anti-fibrotic therapy. These patient populations represent the target audience for TTI-101 and TTI-109, which are intended to address core pathophysiological processes such as tumor proliferation, immune dysregulation, fibroblast activation, and extracellular matrix deposition.